June 10, 2020 06:43 AM EDTUpdated 10:49 AM
Deals

An­a­lysts cheer as Ab­b­Vie pays $750M cash to al­ly it­self with Gen­mab on a pipeline of can­cer drugs, with bil­lions more on the ta­ble

John Carroll

Editor & Founder

You can count the R&D ex­ecs at Ab­b­Vie among the be­liev­ers in Gen­mab’s bis­pe­cif­ic plat­form tech.

Mov­ing be­yond the Al­ler­gan buy­out, Ab­b­Vie re­fo­cused on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Out­look's shares crash as wet AMD drug flunks Phase 3 test

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times